The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Testing has shown reduced bioavailability due to impurities and fibril formation, rendering these products less effective ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00. The firm maintained a Buy ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback